Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 7786 to 7795 of 7795 results

  1. NICE recommends new drug for people living with obesity

    Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.

  2. Thousands of appointments released for the NHS without compromising safety

    Delivering fewer radiotherapy sessions over a shorter period of time, first introduced during COVID, benefits patients and the system long-term

  3. Children and young people set to benefit from new treatment for peanut allergy

    Children and young people aged between 4 and 17 with a peanut allergy could benefit from Palforzia, a new treatment which can help build up their tolerance to peanut.

  4. The key to effective shared decision making is to involve people in meaningful conversations about their choices

    "Tell me and I forget. Teach me and I remember. Involve me and I learn." Benjamin Franklin.

  5. Hundreds of thousands set to benefit from new treatment to prevent heart attacks and strokes

    NICE has published final draft guidance which recommends icosapent ethyl for reducing the risk of heart attacks and strokes in adults who have raised blood fats.

  6. More than 400 people could benefit from life-extending advanced lung cancer treatment

    Durvalumab recommended as an option for treating non-small-cell lung cancer.

  7. More people with rare genetic disorder eligible for nusinersen

    Following a review of data collected as part of the Managed Access Agreement, more people with spinal muscular atrophy (SMA) are to benefit from nusinersen.

  8. Further treatment option for triple-negative breast cancer recommended

    NICE has today (8 November 2022) published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.

  9. Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer

    Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer

  10. Risdiplam not recommend for treating spinal muscular atrophy

    NICE has today (2 June 2021) published draft guidance for which does not recommend risdiplam for treating the rare genetic disorder spinal muscular atrophy (SMA).